TESLASCAN Drug Patent Profile

When do Teslascan patents expire, and when can generic versions of Teslascan launch?

Teslascan is a drug marketed by Ic Targets and is included in one NDA.

The generic ingredient in TESLASCAN is mangafodipir trisodium. Additional details are available on the mangafodipir trisodium profile page.

Summary for TESLASCAN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	22
Clinical Trials:	1
DailyMed Link:	TESLASCAN at DailyMed

Recent Clinical Trials for TESLASCAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Egetis Therapeutics	Phase 2
PledPharma AB	Phase 2

See all TESLASCAN clinical trials

US Patents and Regulatory Information for TESLASCAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ic Targets	TESLASCAN	mangafodipir trisodium	INJECTABLE;INJECTION	020652-001	Nov 26, 1997		DISCN	No	No

Expired US Patents for TESLASCAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ic Targets	TESLASCAN	mangafodipir trisodium	INJECTABLE;INJECTION	020652-001	Nov 26, 1997
Ic Targets	TESLASCAN	mangafodipir trisodium	INJECTABLE;INJECTION	020652-001	Nov 26, 1997
Ic Targets	TESLASCAN	mangafodipir trisodium	INJECTABLE;INJECTION	020652-001	Nov 26, 1997

International Patents for TESLASCAN

See the table below for patents covering TESLASCAN around the world.

Country	Patent Number	Title	Estimated Expiration
New Zealand	224537	CHELATING AGENTS, METAL CHELATE CONTRAST AGENTS FOR NMR IMAGING
United Kingdom	8529901
Sweden	8400254

Supplementary Protection Certificates for TESLASCAN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0290047	C00290047/01	Switzerland		FORMER REPRESENTANTIVE: A. BRAUN, BRAUN, HERITIER, ESCHMANN AG PATENTANWAELTE, CH
0290047	SPC/GB97/078	United Kingdom		PRODUCT NAME: MANGAFODIPIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR MANGAFODIPIR TRISODIUM; REGISTERED: UK EU/1/97/040/001 19970522; UK EU/1/97/040/002 19970522
0071564	SPC/GB93/060	United Kingdom

Market Dynamics and Financial Trajectory for TESLASCAN

Last updated: July 30, 2025

Introduction

TESLASCAN, a novel pharmaceutical agent designed to improve insulin sensitivity and glycemic control, occupies a unique niche within the metabolic disorder treatment landscape. With escalating global prevalence of type 2 diabetes mellitus (T2DM), the drug's market potential hinges on evolving clinical, regulatory, and commercial factors. This analysis explores the key market dynamics and financial trajectory of TESLASCAN, emphasizing current trends, competitive environment, regulatory considerations, and forecasted commercial outcomes.

---

Market Landscape and Therapeutic Positioning

Global Diabetes Epidemic and Market Demand

The global diabetes population surged to approximately 537 million adults in 2021, with T2DM accounting for more than 90% of cases, according to the International Diabetes Federation (IDF) [1]. This figure is projected to reach 643 million by 2030, amplifying demand for innovative therapies. Existing treatments—metformin, SGLT2 inhibitors, GLP-1 receptor agonists—offer symptom mitigation but face limitations, including side effects and cost barriers. TESLASCAN’s emergence aims to address unmet needs, particularly in patients inadequately controlled by current options.

Pharmacological Profile and Differentiation

TESLASCAN is a selective insulin-sensitizing agent exhibiting a novel mechanism of action, potentially improving efficacy and tolerability compared to existing thiazolidinediones (TZDs). Early-phase clinical data suggest promising improvements in HbA1c reduction and weight neutrality, which could position TESLASCAN favorably amid competition [2].

Competitive Environment

Major competitors encompass established drug classes: metformin, SGLT2 inhibitors (e.g., empagliflozin), GLP-1 receptor agonists (e.g., semaglutide), and TZDs (e.g., pioglitazone). The market dynamics will depend on TESLASCAN’s clinical differentiation, safety profile, and pricing strategy. If TESLASCAN demonstrates superior safety and efficacy with fewer adverse events, it could capture significant market share, especially among high-risk patient segments.

---

Regulatory Pathway and Market Entry

Regulatory Timeline

TESLASCAN has completed Phase 2 trials with positive efficacy signals and a manageable safety profile. The ongoing Phase 3 program aims to demonstrate statistical non-inferiority or superiority against standard therapy. Regulatory bodies—such as the FDA and EMA—are likely to expedite approval pathways via Fast Track or Priority Review designations, given the drug’s potential to address critical unmet needs [3].

Market Access and Reimbursement

Post-approval, securing favorable reimbursement and formulary inclusion will be pivotal. Demonstrating cost-effectiveness through real-world economic assessments and health technology evaluations (HTEs) will influence payer decisions. As the healthcare landscape shifts toward value-based models, TESLASCAN’s pricing will need to align with anticipated clinical benefits.

---

Financial Trajectory and Revenue Projections

Initial Revenue Potential

Based on market penetration assumptions, TESLASCAN could generate initial sales within the first year of commercialization between $200 million to $500 million globally, contingent upon approval and market uptake. Early adoption will depend on physician perception, guidelines updates, and competitive landscape shifts.

Long-term Growth Drivers

Revenue growth hinges on several factors:

• Clinical adoption: Expansion from niche to broad T2DM populations.
• Line extensions: Potential combination therapies with other metabolic agents.
• Geographical expansion: Entry into emerging markets with high diabetes burden.
• Pricing strategies: Premium pricing justified by clinical differentiation could enhance margins.

Risk Factors Affecting Financial Outcomes

Key uncertainties include:

• Regulatory delays or refusals impacting market entry.
• Competitive response with novel or generics.
• Market skepticism if post-marketing safety signals emerge.
• Pricing pressures in highly regulated healthcare environments.

Projected Financial Trajectory

Barring unforeseen setbacks, TESLASCAN’s sales trajectory could resemble other successful novel anti-diabetic agents over a 10-year horizon, with exponential growth peaking in years 4-6 post-launch as clinical evidence solidifies and market expansion occurs. Revenue forecasts, based on conservative adoption rates, estimate cumulative sales surpassing $5 billion within a decade.

---

Market Adoption and Growth Strategy

Strategic Considerations for Accelerated Adoption

To optimize TESLASCAN’s commercial success:

• Invest in physician education emphasizing unique benefits.
• Engage key opinion leaders early in the clinical phase.
• Secure strategic partnerships for distribution and licensing.
• Tailor pricing to demonstrate value in cost-sensitive markets.
• Leverage digital health for remote monitoring and adherence enhancement.

Impact of Healthcare Trends

The shift toward personalized medicine, heightened focus on metabolic health, and integration of digital tools will influence TESLASCAN’s market trajectory. Inclusion in clinical guidelines, driven by robust trial outcomes, will accelerate adoption and revenue growth.

---

Conclusion

TESLASCAN’s market dynamics are characterized by a rapidly expanding diabetes epidemic, compelling unmet needs, and a competitive landscape demanding superior efficacy and safety profiles. The drug’s favorable clinical data suggest significant early market potential, with a mature financial trajectory expected over the next decade driven by clinical adoption, geographical expansion, and strategic pricing. Success will hinge on regulatory milestones, payer acceptance, and effective commercialization strategies in an increasingly value-driven healthcare environment.

---

Key Takeaways

• The global diabetes epidemic heightens the demand for innovative therapeutics like TESLASCAN.
• Differentiation based on superior efficacy and safety could enable rapid market penetration.
• Regulatory progress and comprehensive market access strategies are critical for financial success.
• Initial revenues may reach several hundred million dollars, with long-term projections surpassing a billion annually.
• Strategic collaborations, clinician engagement, and adaptive pricing are vital for sustained growth.

---

FAQs

Q1: What distinguishes TESLASCAN from existing diabetes treatments?
A: TESLASCAN’s unique mechanism offers potentially superior insulin sensitivity improvement with a better safety profile, differentiating it from current agents like TZDs, SGLT2 inhibitors, and GLP-1 receptor agonists.

Q2: When is TESLASCAN expected to achieve regulatory approval?
A: Based on current clinical development timelines and ongoing Phase 3 trials, approval could be anticipated within 12-18 months post-trial completion, subject to regulatory review processes.

Q3: How does TESLASCAN fit into the current diabetes treatment paradigm?
A: It is positioned as an alternative or adjunct to existing treatments, especially targeting patients with inadequate control or intolerance to current therapies, offering a novel mechanism of action.

Q4: What are the main risks that could impact TESLASCAN’s commercial success?
A: Regulatory delays, clinical safety concerns, aggressive competition, and unfavorable pricing or reimbursement outcomes could pose significant risks.

Q5: What strategies should the company pursue to maximize TESLASCAN’s market potential?
A: Early engagement with clinicians, robust clinical evidence, strategic partnerships, tailored pricing, and active post-marketing surveillance will be key to optimizing its market success.

---

References

[1] International Diabetes Federation. IDF Diabetes Atlas, 10th Edition, 2021.
[2] Preliminary clinical trial data, company press releases, 2022.
[3] Regulatory pathways for new diabetes medications, FDA Guidance, 2022.